Search the PBPK Model Repository

Quickly find freely available drug and population models in our PBPK model repository.

The models provided have been collated from published examples which authors have shared in our Published Model Collection or developed as part of various global health projects in our Global Health Collection. This search facility searches both model collections simultaneously.

To contribute published user compound and/or population files, upload your files here: Upload Model Files

Searching Tips

You can use a * character as a wildcard at the end of a alphanumeric search term. The search term must start with at least one character before the wildcard. E.g., Rifam* will get you “Rifampicin” and “Rifampin”.
You can also use a * character as a wildcard in the middle of a alphanumeric search term. The search term must still start with at least one character before the wildcard. E.g., Rif*in will also get you “Rifampicin” and “Rifampin” .
You can also use a * character as a wildcard at the start of a alphanumeric search term. However you must use forward slashes to delimit the search term and use a point before the wildcard. E.g., /.*picin/ will only get you “Rifampicin”.

A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Found 108 Matches

Rosuvastatin_Itraconazole_OH-Itraconazole_V19R1_Pfizer_20210804

Model Files Publication

An optimized Rosuvastatin (V19) model was used and DDIs predominantly driven by gut BCRP inhibition are reasonably recovered. Altogether, the following inhibitors were used: Capmatinib Fenebrutinib Fostamatinib Itraconazole Zepatier The workspace represents the DDI between Rosuvastatin and Itraconazole. Link to the publication with further details: http://doi.org/10.1002/psp4.12672

Search Score: 1

Sitagliptin_V15R1_USFDA_20170810

Model Files Publication

http://onlinelibrary.wiley.com/doi/10.1002/cpt.750/full Sitagliptin compound file in healthy volunteers. Evaluation of the effect of renal impairment on the PK of OAT substrates. NOTE: in the model Ka is 0.29, Peff is 0.18. Different from Table 1.

Search Score: 1

Sulfamethoxazole_MechKiM_V16R1_UniversityOfManchester_20210421

Model Files Publication

https://doi.org/10.1124/jpet.118.251413 Sulfamethoxazole compound file with MechKiM

Search Score: 1

Enfuviridine

Model Files Publication

Brand Name(s) include: Fuzeon

Disease: HIV

Drug Class: HIV Entry and Fusion Inhibitor

Date of Review: 2020

Number of Models Reviewed: 1

Number of Models added to the Repository: 1

The model at-a-glance

Publication	Pan, X., Stader, F., Abduljalil, K., Gill, K. L., Johnson, T. N., Gardner, I., & Jamei, M. (2020). Development and Application of a Physiologically-Based Pharmacokinetic Model to Predict the Pharmacokinetics of Therapeutic Proteins from Full-term Neonates to Adolescents. The AAPS journal, 22(4), 76.
Simcyp Version	V18
Published Model Application	Prediction of exposure in noenates
Absorption Model	First Order
Volume of Distribution Details	Full PBPK
Route of Elimination	Renal filtration Additional systemic clearance
Perpetrator DDI	None
Advantages and Limitations	Model was developed to predict the PK of enfuviridine in neonates and adolescents. Model was verified in adult and pediatric populations. Model was verified for IV and subcutaneous dosing. Model was developed in V18. Due to changes in the Simulator, the model would need to be revalidated for use in V20 and subsequent versions.
Model Compound Files	v18_res_enfuviridine_simcyp_pan v18_res_enfuviridine_simcyp_pan_sc_paed

Search Score: 1

Search the PBPK Model Repository

Searching Tips

Rosuvastatin_Itraconazole_OH-Itraconazole_V19R1_Pfizer_20210804

Sitagliptin_V15R1_USFDA_20170810

Sulfamethoxazole_MechKiM_V16R1_UniversityOfManchester_20210421

Enfuviridine

The model at-a-glance

Your Privacy